(Q45239470)

English

An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma

scientific article published in March 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

based on heuristic

inferred from title

author name string

Nicholas Di Bella

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Craig Reynolds

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

David Faragher

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Joseph Muscato

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Kristi A Boehm

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Lina Asmar

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

103

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

978-984

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

21 January 2018

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

New treatment approaches to indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of non-Hodgkin's lymphomas in elderly patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Pentostatin (2′-Deoxycoformycin, dCF) in Patients with Low-Grade (B-T-Cell) and Intermediate- and High-Grade (T-Cell) Malignant Lymphomas: Phase II Study of the EORTC Early Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

2' Deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: a CALGB phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose deoxycoformycin in lymphoid malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Pentostatin (2'-deoxycoformycin) for the treatment of lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20820

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20820

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45239470&oldid=2070974447"